US7252829B1
(en)
*
|
1998-06-17 |
2007-08-07 |
Idm Pharma, Inc. |
HLA binding peptides and their uses
|
AU712441B2
(en)
*
|
1994-12-14 |
1999-11-04 |
Scripps Research Institute, The |
In vivo activation of tumor-specific cytotoxic T cells
|
US6514942B1
(en)
*
|
1995-03-14 |
2003-02-04 |
The Board Of Regents, The University Of Texas System |
Methods and compositions for stimulating T-lymphocytes
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
NZ332588A
(en)
*
|
1996-05-15 |
2000-11-24 |
Altarex Inc |
Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer
|
US20080220012A1
(en)
*
|
1996-05-15 |
2008-09-11 |
Ragupathy Madiyalakan |
Therapeutic Compositions that alter the immune response
|
US8038994B2
(en)
|
1996-05-15 |
2011-10-18 |
Quest Pharmatech Inc. |
Combination therapy for treating disease
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
EP0963435B1
(de)
|
1997-01-08 |
2008-05-28 |
Invitrogen Corporation |
Verfahren zur herstellung von proteinen
|
US6884435B1
(en)
*
|
1997-01-30 |
2005-04-26 |
Chiron Corporation |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
US20040202680A1
(en)
*
|
1997-01-30 |
2004-10-14 |
O'hagan Derek |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
EP0991403B1
(de)
*
|
1997-01-30 |
2003-04-02 |
Chiron Corporation |
Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
WO1999057981A1
(en)
*
|
1998-05-08 |
1999-11-18 |
Sloan-Kettering Institute For Cancer Research |
Compositions and methods for active vaccination
|
GB9810040D0
(en)
*
|
1998-05-11 |
1998-07-08 |
Univ Nottingham |
Blood borne tumour markers
|
CN1689646A
(zh)
|
1998-08-11 |
2005-11-02 |
拜奥根Idec公司 |
包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
|
US6573043B1
(en)
*
|
1998-10-07 |
2003-06-03 |
Genentech, Inc. |
Tissue analysis and kits therefor
|
CA2350064C
(en)
*
|
1998-11-09 |
2012-05-08 |
Idec Pharmaceuticals Corporation |
Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants
|
DK2055313T3
(en)
*
|
1998-11-09 |
2015-07-27 |
Biogen Inc |
Treatment of Hematologic Malignancies Related to Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody
|
US6541214B1
(en)
*
|
1998-11-13 |
2003-04-01 |
Oregon Heath Science University |
N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
|
GB9827228D0
(en)
|
1998-12-10 |
1999-02-03 |
Univ Nottingham |
Cancer detection method and reagents
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
US7396810B1
(en)
*
|
2000-08-14 |
2008-07-08 |
Oregon Health Sciences University |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
|
US7625859B1
(en)
*
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
CA2357525A1
(en)
|
1999-01-27 |
2000-08-03 |
Cornell Research Foundation, Inc. |
Treating cancers associated with overexpression of her-2/neu
|
US7198920B1
(en)
*
|
1999-01-29 |
2007-04-03 |
Corika Corporation |
HER-2/neu fusion proteins
|
CN1201004C
(zh)
*
|
1999-01-29 |
2005-05-11 |
考丽克萨有限公司 |
HER-2/neu融合蛋白
|
AU3755800A
(en)
*
|
1999-03-15 |
2000-10-04 |
Introgen Therapeutics, Inc. |
Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
|
EP1754488A1
(de)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
|
EP1187849A1
(de)
*
|
1999-05-25 |
2002-03-20 |
Human Genome Sciences, Inc. |
Meth1 und meth2 polynukleotide und polypeptide
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
CN100381172C
(zh)
*
|
1999-06-25 |
2008-04-16 |
吉尼泰克公司 |
使用抗-ErbB2抗体治疗前列腺癌
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
AU6620300A
(en)
*
|
1999-08-03 |
2001-02-19 |
Ohio State University, The |
Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
US6627196B1
(en)
*
|
1999-08-27 |
2003-09-30 |
Genentech, Inc. |
Dosages for treatment with anti-ErbB2 antibodies
|
WO2001021192A2
(en)
*
|
1999-09-22 |
2001-03-29 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
US20030157119A1
(en)
*
|
1999-09-22 |
2003-08-21 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
JP2003510334A
(ja)
*
|
1999-09-30 |
2003-03-18 |
コリクサ コーポレイション |
癌及び感染症の予防及び治療のためのストレスタンパク質組成物及び方法
|
US7378096B2
(en)
|
1999-09-30 |
2008-05-27 |
Health Research, Inc. |
Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
|
FR2801106B1
(fr)
*
|
1999-11-12 |
2007-10-05 |
Commissariat Energie Atomique |
Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
|
EP1239866A4
(de)
*
|
1999-12-10 |
2005-02-09 |
Epimmune Inc |
Induzierung von zellulärer immunantwort auf her2/neu mit hilfe von peptid- und neukleinsäurezubereitungen
|
WO2001048205A2
(en)
*
|
1999-12-29 |
2001-07-05 |
Corixa Corporation |
Murine neu sequences and methods of use therefor
|
US20020039573A1
(en)
*
|
2000-01-21 |
2002-04-04 |
Cheever Martin A. |
Compounds and methods for prevention and treatment of HER-2/neu associated malignancies
|
US6528060B1
(en)
*
|
2000-03-16 |
2003-03-04 |
Genzyme Corporation |
Therapeutic compounds
|
PT1272633E
(pt)
*
|
2000-03-30 |
2011-06-27 |
Dendreon Corp |
Composições e métodos para imunoterapia baseada em células dendríticas
|
CA2405290C
(en)
*
|
2000-04-13 |
2011-06-21 |
Bio Life Science Forschungs Und Entwicklungsgesellschaft Mbh |
Vaccine against cancerous diseases
|
WO2001083781A2
(en)
*
|
2000-04-28 |
2001-11-08 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
ATE441433T1
(de)
|
2000-05-19 |
2009-09-15 |
Genentech Inc |
Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb- antagonisten
|
US10293056B1
(en)
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
US20030232399A1
(en)
*
|
2000-06-14 |
2003-12-18 |
Robertson John Forsyth Russell |
Cancer detection methods and reagents
|
FR2812087B1
(fr)
*
|
2000-07-21 |
2007-05-11 |
Inst Nat Sante Rech Med |
Procede de criblage de peptides utilisables en immunotherapie
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
CN1537164A
(zh)
*
|
2000-08-14 |
2004-10-13 |
|
治疗和诊断Her-2/neu相关恶性肿瘤的组合物和方法
|
WO2002013847A2
(en)
*
|
2000-08-14 |
2002-02-21 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
EP2266603B1
(de)
|
2000-10-18 |
2012-09-12 |
GlaxoSmithKline Biologicals S.A. |
Impfstoffe gegen Krebs
|
EP1404359A2
(de)
*
|
2000-12-07 |
2004-04-07 |
Board Of Regents, The University Of Texas System |
Behandlungsverfahren mit menschlichem mda-7
|
US20040121946A9
(en)
*
|
2000-12-11 |
2004-06-24 |
John Fikes |
Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
|
US7507724B2
(en)
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US7906492B2
(en)
*
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
DE60226853D1
(de)
|
2001-02-20 |
2008-07-10 |
Ortho Mcneil Pharm Inc |
Zelltherapieverfahren für die behandlung von tumoren
|
US20040071671A1
(en)
*
|
2001-02-20 |
2004-04-15 |
Leturcq Didier J. |
Cell therapy method for the treatment of tumors
|
EP1236740B1
(de)
*
|
2001-02-28 |
2012-07-18 |
Bio Life Science Forschungs- und Entwicklungsges.m.b.H. |
Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
|
DK2371854T3
(da)
*
|
2001-03-09 |
2014-08-11 |
Univ Texas |
Induktion af tumorimmunitet med varianter af folatbindende protein
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP1399183B1
(de)
|
2001-05-31 |
2010-06-30 |
Novartis Vaccines and Diagnostics, Inc. |
Chimere alphavirus-replikon-partikel
|
ATE345812T1
(de)
*
|
2001-09-03 |
2006-12-15 |
Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh |
Antigen-mimotope und vakzine gegen krebserkrankungen
|
ATE443259T1
(de)
|
2001-09-20 |
2009-10-15 |
Univ Texas |
Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
|
CA2477780A1
(en)
*
|
2002-03-05 |
2003-09-18 |
Board Of Regents, The University Of Texas System |
Methods of enhancing immune induction involving mda-7
|
US8802618B2
(en)
*
|
2002-03-08 |
2014-08-12 |
Board Of Regents, The University Of Texas System |
Controlled modulation of amino acid side chain length of peptide antigens
|
AU2003223600A1
(en)
*
|
2002-04-11 |
2003-10-27 |
Altarex Medical Corporation |
Binding agents and their use in targeting tumor cells
|
AU2003251597A1
(en)
*
|
2002-06-19 |
2004-01-06 |
Abgenix, Inc. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
US9200036B2
(en)
|
2002-07-12 |
2015-12-01 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
US20090110702A1
(en)
|
2002-07-12 |
2009-04-30 |
The Johns Hopkins University |
Mesothelin Vaccines and Model Systems and Control of Tumors
|
US20050175625A1
(en)
|
2002-07-12 |
2005-08-11 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
CN101912421A
(zh)
|
2002-08-12 |
2010-12-15 |
杰能斯有限公司 |
涉及痘病毒和癌的方法及组合物
|
US20080019992A1
(en)
*
|
2002-09-02 |
2008-01-24 |
Christoph Zielinski |
Antigen mimotopes and vaccine against cancerous diseases
|
CN1497255A
(zh)
*
|
2002-10-02 |
2004-05-19 |
���µ�����ҵ��ʽ���� |
被检测体用取样元件、被检测体处理装置及其处理方法
|
AU2003267077A1
(en)
*
|
2002-11-12 |
2004-06-03 |
Millipore Corporation |
Evaporation control device for multiwell plates
|
GB2424273B
(en)
*
|
2002-11-14 |
2007-06-27 |
Univ Nottingham |
Method for preparing tumour marker protein
|
WO2004048525A2
(en)
*
|
2002-11-21 |
2004-06-10 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
|
WO2004061105A1
(en)
|
2003-01-03 |
2004-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Rhesus her2/neu, nucleotides encoding same, and uses thereof
|
WO2004067716A2
(en)
*
|
2003-01-24 |
2004-08-12 |
Agensys, Inc. |
Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
|
EP1603943A2
(de)
*
|
2003-03-03 |
2005-12-14 |
Board of Regents, The University of Texas System |
Verfahren und zusammensetzungen mit mda-7
|
DK1620456T3
(da)
|
2003-04-18 |
2014-04-22 |
Biotech Synergy Inc |
Hla-a2 tumor-associerede antigen-peptider og præparater
|
US20050239088A1
(en)
*
|
2003-05-16 |
2005-10-27 |
Shepard H M |
Intron fusion proteins, and methods of identifying and using same
|
US7178491B2
(en)
*
|
2003-06-05 |
2007-02-20 |
Caterpillar Inc |
Control system and method for engine valve actuator
|
WO2004112825A2
(en)
*
|
2003-06-17 |
2004-12-29 |
Mannkind Corporation |
Combinations of tumor-associated antigens for the treatment of various types of cancers
|
JP4772674B2
(ja)
*
|
2003-07-21 |
2011-09-14 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ヒト上皮成長因子2/neu抗原をコードする合成遺伝子およびその用途
|
GB0321615D0
(en)
|
2003-09-15 |
2003-10-15 |
Glaxo Group Ltd |
Improvements in vaccination
|
CN1901795B
(zh)
|
2003-10-22 |
2014-03-26 |
弗雷德哈钦森癌症研究中心 |
用于在细胞,组织,器官,和有机体中诱导停滞的方法,组合物和装置
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
CA2548220A1
(en)
*
|
2003-12-01 |
2005-09-09 |
Introgen Therapeutics, Inc. |
Use of mda-7 to inhibit infection by pathogenic organisms
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
AU2005245896A1
(en)
*
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
EP2471922A1
(de)
|
2004-05-28 |
2012-07-04 |
Asuragen, Inc. |
Verfahren und Zusammensetzungen mit microRNA
|
KR101200133B1
(ko)
|
2004-06-01 |
2012-11-13 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
CA2580141C
(en)
|
2004-09-23 |
2013-12-10 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
WO2006042002A2
(en)
*
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
ATE497165T1
(de)
*
|
2004-10-06 |
2011-02-15 |
Wellstat Biologics Corp |
Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung
|
US8173611B2
(en)
|
2004-11-12 |
2012-05-08 |
Asuragen Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
US20060115862A1
(en)
*
|
2004-11-17 |
2006-06-01 |
Duke University |
Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
|
CN100381460C
(zh)
*
|
2004-11-30 |
2008-04-16 |
北京市肿瘤防治研究所 |
Her-2模拟抗原表位及含有该表位的肽
|
CA2594224A1
(en)
*
|
2004-12-29 |
2006-07-06 |
Mannkind Corporation |
Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
|
CN101166539B
(zh)
*
|
2005-02-08 |
2012-01-04 |
得克萨斯大学体系董事会 |
用于治疗癌症的涉及mda-7的组合物和方法
|
AU2006236150A1
(en)
*
|
2005-04-20 |
2006-10-26 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
|
CN100398558C
(zh)
*
|
2005-05-10 |
2008-07-02 |
中国人民解放军军事医学科学院基础医学研究所 |
HER2/neu与Herstatin相互作用的活性片段及其编码基因与应用
|
AU2006249199A1
(en)
*
|
2005-05-12 |
2006-11-23 |
Introgen Therapeutics, Inc. |
P53 vaccines for the treatment of cancers
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
GB2426581A
(en)
*
|
2005-05-27 |
2006-11-29 |
Univ Nottingham |
Immunoassay methods
|
RU2636532C2
(ru)
|
2005-05-27 |
2017-11-23 |
Онкиммьюн Лимитед |
Улучшенные способы иммуноанализа
|
WO2006138675A2
(en)
|
2005-06-15 |
2006-12-28 |
The Ohio State University Research Foundation |
Her-2 peptides
|
KR20080026181A
(ko)
|
2005-06-17 |
2008-03-24 |
맨카인드 코포레이션 |
암세포 및 종양 기질에 발현된 우성 및 준우성 에피토프에대한 다가 면역반응을 유발하기 위한 방법 및 조성물
|
GB0512751D0
(en)
*
|
2005-06-22 |
2005-07-27 |
Glaxo Group Ltd |
New adjuvant
|
WO2007030668A2
(en)
*
|
2005-09-07 |
2007-03-15 |
Jennerex Biotherapeutics Ulc |
Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
|
WO2007030451A2
(en)
*
|
2005-09-07 |
2007-03-15 |
Receptor Logic, Ltd. |
Antibodies as t cell receptor mimics, methods of production and uses thereof
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
US8945573B2
(en)
|
2005-09-08 |
2015-02-03 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Targeted identification of immunogenic peptides
|
ES2628308T3
(es)
*
|
2005-09-08 |
2017-08-02 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Identificación selectiva de péptidos inmunogénicos
|
EP2357000A1
(de)
|
2005-10-18 |
2011-08-17 |
Novartis Vaccines and Diagnostics, Inc. |
Mukosale und systemische Immunisierungen mit Alphavirus-Replikonpartikeln
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
WO2007084661A2
(en)
*
|
2006-01-17 |
2007-07-26 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US8323644B2
(en)
*
|
2006-01-17 |
2012-12-04 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US20090053221A1
(en)
*
|
2006-01-17 |
2009-02-26 |
Cheung Nai-Kong V |
Immune response enhancing glucan
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
US8063063B2
(en)
*
|
2006-03-23 |
2011-11-22 |
Novartis Ag |
Immunopotentiating compounds
|
EP2010530A2
(de)
*
|
2006-03-23 |
2009-01-07 |
Novartis AG |
Herstellungsverfahren für imidazolhaltige verbindungen
|
ES2536426T3
(es)
|
2006-03-23 |
2015-05-25 |
Novartis Ag |
Compuestos de imidazoquinoxalina como inmunomoduladores
|
US7517270B2
(en)
*
|
2006-05-30 |
2009-04-14 |
Minds-I, Inc. |
Construction system
|
WO2008042495A2
(en)
|
2006-07-21 |
2008-04-10 |
Life Technologies Corporation |
Sharply resolving labeled protein molecular weight standards
|
US7972602B2
(en)
|
2006-08-11 |
2011-07-05 |
Dendreon Corporation |
Promiscuous HER-2/Neu CD4 T cell epitopes
|
US8574848B2
(en)
*
|
2006-09-13 |
2013-11-05 |
Oncimmune Ltd. |
Immunoassay methods
|
CA2663034C
(en)
|
2006-09-15 |
2016-05-03 |
Ottawa Health Research Institute |
Oncolytic rhabdovirus
|
CA2663962A1
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
US20080075528A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Michael Marzetta |
Construction system
|
US8129184B2
(en)
*
|
2006-09-26 |
2012-03-06 |
Cedars-Sinai Medical Center |
Cancer stem cell antigen vaccines and methods
|
WO2008039974A2
(en)
|
2006-09-28 |
2008-04-03 |
Cedars-Sinai Medical Center |
Cancer vaccines and vaccination methods
|
US20080131878A1
(en)
*
|
2006-12-05 |
2008-06-05 |
Asuragen, Inc. |
Compositions and Methods for the Detection of Small RNA
|
AU2007333106A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
miR-20 regulated genes and pathways as targets for therapeutic intervention
|
US7935350B2
(en)
*
|
2006-12-14 |
2011-05-03 |
Antigen Express, Inc. |
Ii-key/Her-2/neu hybrid cancer vaccine
|
US8889143B2
(en)
|
2006-12-14 |
2014-11-18 |
Antigen Express, Inc. |
Ii-key/HER-2/neu hybrid cancer vaccine
|
US7410225B1
(en)
*
|
2007-03-14 |
2008-08-12 |
Minds-I, Inc. |
Multi-part links for endless track
|
KR20080084528A
(ko)
*
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
MX2009011228A
(es)
*
|
2007-04-19 |
2009-11-02 |
Wellstat Biologics Corp |
Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
|
US8222214B2
(en)
*
|
2007-06-01 |
2012-07-17 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Vaccine for the prevention of breast cancer relapse
|
US20090017716A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Michael Marzetta |
Construction system
|
US20090061456A1
(en)
*
|
2007-08-30 |
2009-03-05 |
Allard William J |
Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
|
US8361714B2
(en)
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
US20090117532A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Doyle Gerald V |
Pre-clinical method for monitoring serial changes in circulating breast cancer cells in mice
|
WO2009059450A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Shanghai Jiaotong University |
Peptide ligand directed drug delivery
|
US7841923B2
(en)
*
|
2007-11-13 |
2010-11-30 |
Minds-I, Inc. |
Vehicle axle joint for a toy vehicle
|
CN101878429B
(zh)
|
2007-11-27 |
2015-05-20 |
维里德克斯有限责任公司 |
血液中循环黑素瘤细胞的自动化计数和表征
|
WO2009070805A2
(en)
|
2007-12-01 |
2009-06-04 |
Asuragen, Inc. |
Mir-124 regulated genes and pathways as targets for therapeutic intervention
|
US20090191535A1
(en)
*
|
2007-12-22 |
2009-07-30 |
Mark Carle Connelly |
Method of assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
|
GB0725239D0
(en)
*
|
2007-12-24 |
2008-02-06 |
Oncimmune Ltd |
Calibrator for autoantibody assay
|
WO2009137807A2
(en)
|
2008-05-08 |
2009-11-12 |
Asuragen, Inc. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
JP2010006705A
(ja)
*
|
2008-06-13 |
2010-01-14 |
Atlas Antibodies Ab |
Her2サブセット
|
EP2328923B1
(de)
|
2008-09-02 |
2016-01-13 |
Cedars-Sinai Medical Center |
Cd133-epitope
|
BRPI0922849B1
(pt)
|
2008-12-10 |
2023-01-24 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc |
Composição de vacina com uma quantidade eficaz de um peptídeo gp2 e de gm-csf
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
AU2010248884B2
(en)
*
|
2009-05-14 |
2015-04-02 |
Nestec S.A. |
Biomarkers for determining sensitivity of breast cancer cells to HER2-targeted therapy
|
WO2010144874A2
(en)
|
2009-06-12 |
2010-12-16 |
University Of Southern California |
Clusterin pharmaceuticals and treatment methods using the same
|
IN2012DN03025A
(de)
|
2009-09-09 |
2015-07-31 |
Ct Se Llc |
|
CA2774144C
(en)
|
2009-09-14 |
2018-02-13 |
Jennerex, Inc. |
Oncolytic vaccinia virus combination cancer therapy
|
CN102858959B
(zh)
|
2009-12-10 |
2016-02-24 |
渥太华医院研究院 |
溶瘤弹状病毒
|
WO2011107100A1
(en)
|
2010-03-03 |
2011-09-09 |
Aarhus Universitet |
Methods and compositions for regulation of herv4
|
BR112012026213B1
(pt)
|
2010-04-15 |
2021-12-28 |
Medimmune Limited |
Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
|
WO2011154863A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
CA2799540A1
(en)
|
2010-06-08 |
2011-12-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JP5889912B2
(ja)
|
2010-11-17 |
2016-03-22 |
ジェネンテック, インコーポレイテッド |
アラニニルメイタンシノール抗体コンジュゲート
|
BR112013017096A2
(pt)
|
2011-01-04 |
2020-09-01 |
Jennerex Inc. |
composição e métodos de indução de resposta citotóxica dependente de complemento mediado por anticorpo específico de tumor em animal tendo tumor, de geração de anticorpos in vivo, de inibição do crescimento ou morte de célula de câncer, para tratar indivíduo com câncer, para adaptar de terapia de câncer para indivíduo com câncer e para identificar antígeno específico de tumor
|
AU2012212023B9
(en)
|
2011-02-03 |
2017-01-12 |
Mirna Therapeutics, Inc. |
Synthetic mimics of miR-34
|
CA2826043A1
(en)
|
2011-02-03 |
2012-08-09 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-124
|
CA2833212C
(en)
|
2011-05-12 |
2020-06-09 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
|
WO2012167382A1
(en)
|
2011-06-08 |
2012-12-13 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions and methods for glioblastoma treatment
|
EP2739310B1
(de)
|
2011-08-05 |
2018-04-18 |
Research Development Foundation |
Verbesserte verfahren und zusammensetzungen zur modulation von olfml3-vermittelter angiogenese
|
US10258676B2
(en)
|
2011-09-06 |
2019-04-16 |
Agency For Science, Technology And Research |
Polypeptide vaccine
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
KR101877598B1
(ko)
|
2011-10-14 |
2018-07-11 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
AU2013221309B2
(en)
*
|
2012-02-17 |
2017-03-30 |
Mayo Foundation For Medical Education And Research |
Methods and materials for generating CD8+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
WO2013188873A1
(en)
|
2012-06-15 |
2013-12-19 |
Gencia Corporation |
Compositions and methods for enhancing immune responses
|
UA114108C2
(uk)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
|
SI2906296T1
(en)
|
2012-10-12 |
2018-06-29 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
PT2839860T
(pt)
|
2012-10-12 |
2019-07-29 |
Medimmune Ltd |
Pirrolobenzodiazepinas e conjugados das mesmas
|
ES2660029T3
(es)
|
2012-10-12 |
2018-03-20 |
Medimmune Limited |
Conjugados de anticuerpo-pirrolobenzodiazepinas
|
ES2703151T3
(es)
|
2012-10-12 |
2019-03-07 |
Adc Therapeutics Sa |
Conjugados de anticuerpos de pirrolobenzodiazepinas
|
NZ707486A
(en)
|
2012-10-12 |
2018-09-28 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine - anti-psma antibody conjugates
|
EP2906250B1
(de)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate
|
HUE035694T2
(en)
|
2012-10-12 |
2018-05-28 |
Adc Therapeutics Sa |
Pirrolobenzodiazepine anti-CD22 antibody conjugates
|
DK2912064T3
(da)
|
2012-10-24 |
2019-07-22 |
Res Found Dev |
Jam-c-antistoffer og fremgangsmåder til behandling af cancer
|
EA031585B1
(ru)
|
2012-12-21 |
2019-01-31 |
Медимьюн Лимитед |
Пирролобензодиазепины и их конъюгаты
|
CN105246894A
(zh)
|
2012-12-21 |
2016-01-13 |
斯皮罗根有限公司 |
用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
|
US10137182B2
(en)
|
2013-02-14 |
2018-11-27 |
Immunocellular Therapeutics, Ltd. |
Cancer vaccines and vaccination methods
|
RU2684211C2
(ru)
|
2013-02-21 |
2019-04-04 |
Тёрнстоун Лимитед Партнершип |
Композиция вакцины
|
JP6444902B2
(ja)
|
2013-03-13 |
2018-12-26 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン及びその結合体
|
CN105142674B
(zh)
|
2013-03-13 |
2018-11-13 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓和其结合物
|
NZ710745A
(en)
|
2013-03-13 |
2019-03-29 |
Genentech Inc |
Pyrrolobenzodiazepines and conjugates thereof
|
AU2014307080B2
(en)
|
2013-08-12 |
2018-06-07 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
AU2014306592B2
(en)
|
2013-08-14 |
2019-04-04 |
Bristol-Myers Squibb Company |
Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
|
CN114621346A
(zh)
|
2013-08-21 |
2022-06-14 |
德克萨斯州大学系统董事会 |
用于靶向连接蛋白半通道的组合物和方法
|
AU2014312168B2
(en)
|
2013-08-29 |
2020-08-06 |
Board Of Regents, The University Of Texas System |
Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
|
CN113957061A
(zh)
|
2013-08-30 |
2022-01-21 |
得克萨斯大学体系董事会 |
用于肿瘤疗法的犬尿氨酸耗竭酶的施用
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
EP3054985B1
(de)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepin-antikörper-konjugate
|
EP3054983B1
(de)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepin-antikörper-konjugate
|
EP3076949B1
(de)
|
2013-12-04 |
2019-09-04 |
Board of Regents, The University of Texas System |
Verfahren zur isolierung von exosomen abstammend von krebszellen
|
JP6895254B2
(ja)
|
2013-12-16 |
2021-06-30 |
ジェネンテック, インコーポレイテッド |
ペプチド模倣化合物及びその抗体−薬物コンジュゲート
|
CA2928952A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
CA2929565A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
WO2016153761A1
(en)
*
|
2015-03-13 |
2016-09-29 |
Czerniecki Brian J |
Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
|
WO2016190940A1
(en)
*
|
2015-05-22 |
2016-12-01 |
Czerniecki Brian J |
Manufacturing multi-dose injection ready dendritic cell vaccines
|
EP3185860A4
(de)
|
2014-08-29 |
2018-08-29 |
The Board of Regents of the University of Texas System |
Neuartige capsazepinanaloga zur behandlung von krebs und anderen proliferativen erkrankungen
|
IL250833B
(en)
|
2014-08-29 |
2022-09-01 |
Univ Texas |
Administering enzymes to reduce the level of kynurenine in the treatment of tumors
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3191134B1
(de)
|
2014-09-12 |
2019-11-20 |
Genentech, Inc. |
Anthracyclindisulfidzwischenprodukte, antikörper-wirkstoff-konjugate und verfahren
|
US10077318B2
(en)
|
2014-09-12 |
2018-09-18 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
MA40575A
(fr)
|
2014-09-17 |
2016-03-24 |
Genentech Inc |
Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
|
AU2015352545B2
(en)
|
2014-11-25 |
2020-10-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2016090050A1
(en)
|
2014-12-03 |
2016-06-09 |
Genentech, Inc. |
Quaternary amine compounds and antibody-drug conjugates thereof
|
CA2976236A1
(en)
|
2015-02-09 |
2016-08-18 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
MX2017011298A
(es)
|
2015-03-04 |
2018-06-19 |
Univ Texas |
Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53.
|
US20180171294A1
(en)
*
|
2015-03-26 |
2018-06-21 |
The Trustees Of The University Of Pennsylvania |
In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
WO2016196506A1
(en)
|
2015-05-29 |
2016-12-08 |
Galena Biopharma, Inc. |
PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRα-EXPRESSING TUMORS
|
EP3307890A1
(de)
|
2015-06-10 |
2018-04-18 |
Board of Regents, The University of Texas System |
Verwendung von exosomen zur behandlung von krankheiten
|
RU2612015C2
(ru)
*
|
2015-06-29 |
2017-03-01 |
Общество с ограниченной ответственностью "Сибинтех" |
Пептид-иммуноген, используемый в терапевтической вакцине для лечения метастатического рака молочной железы у кошек и собак
|
CA2993823C
(en)
|
2015-07-28 |
2024-01-02 |
Board Of Regents, The University Of Texas System |
Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
KR20180091816A
(ko)
|
2015-10-14 |
2018-08-16 |
바이오-패쓰 홀딩스 인크. |
리포좀 제제를 위한 p-에톡시 핵산
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
RU2624862C2
(ru)
*
|
2015-10-20 |
2017-07-07 |
Общество с ограниченной ответственностью "Эпитек" |
Пептид-иммуноген, используемый в терапевтической вакцине для лечения метастатического рака молочной железы
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
CA3004530A1
(en)
|
2015-11-07 |
2017-05-11 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
WO2017083296A1
(en)
|
2015-11-09 |
2017-05-18 |
The Children's Hospital Of Philadelphia |
Glypican 2 as a cancer marker and therapeutic target
|
CN108925136B
(zh)
|
2015-12-02 |
2022-02-01 |
斯特赛恩斯公司 |
特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体
|
CN109415437B
(zh)
|
2015-12-02 |
2022-02-01 |
斯特库伯株式会社 |
与btn1a1免疫特异性结合的抗体和分子及其治疗用途
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
CN116672445A
(zh)
|
2016-02-26 |
2023-09-01 |
德克萨斯大学体系董事会 |
连接蛋白(Cx)43半通道结合抗体及其用途
|
WO2017151922A1
(en)
|
2016-03-02 |
2017-09-08 |
The Board Of Regents Of The University Of Texas System |
Sting activating nanovaccine for immunotherapy
|
JP6943872B2
(ja)
|
2016-03-25 |
2021-10-06 |
ジェネンテック, インコーポレイテッド |
多重全抗体及び抗体複合体化薬物定量化アッセイ
|
EP3943508B1
(de)
|
2016-03-29 |
2024-01-10 |
Board Of Regents, The University Of Texas System |
Zweifach funktionale antikörper, die spezifisch für glykosyliertes pd-l1 sind, und verfahren zur verwendung davon
|
EP3436475A1
(de)
|
2016-03-29 |
2019-02-06 |
STCube & Co., Inc. |
Verfahren zur auswahl von antikörpern, die spezifisch glykosylierte immunkontrollpunktproteine binden
|
WO2017176076A1
(en)
|
2016-04-06 |
2017-10-12 |
Ewha University - Industry Collaboration Foundation |
A peptide with ability to penetrate cell membrane
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017189976A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Targeted measure of transcriptional activity related to hormone receptors
|
BR112018073671A2
(pt)
|
2016-05-16 |
2019-02-26 |
The Board Of Regents Of The University Of Texas System |
composições para a entrega de rnat como nanopartículas e métodos de uso
|
JP2019522633A
(ja)
|
2016-05-20 |
2019-08-15 |
ジェネンテック, インコーポレイテッド |
Protac抗体コンジュゲート及び使用方法
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
WO2017210255A1
(en)
|
2016-05-31 |
2017-12-07 |
Galena Biopharma, Inc. |
Vaccine therapy for treatment of endometrial and ovarian cancer
|
EP3464560A4
(de)
*
|
2016-06-03 |
2020-01-15 |
Etubics Corporation |
Zusammensetzungen und verfahren für tumorimpfung und immuntherapie mit her2/neu
|
EP3464280B1
(de)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol-antikörper-arzneimittelkonjugate und verfahren zur verwendung
|
JP2019520392A
(ja)
|
2016-07-06 |
2019-07-18 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
ヒト酵素媒介性シスチン枯渇
|
EP3487883B1
(de)
|
2016-07-20 |
2023-01-04 |
Stcube, Inc. |
Verfahren zur krebsbehandlung und therapie unter verwendung einer kombination von glykosyliertes pd-l1-bindenden antikörpern
|
EP3496763A1
(de)
|
2016-08-11 |
2019-06-19 |
Genentech, Inc. |
Pyrrolobenzodiazepin-prodrugs und antikörperkonjugate davon
|
US9963498B2
(en)
|
2016-08-18 |
2018-05-08 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
|
MX2019003070A
(es)
|
2016-09-16 |
2019-10-14 |
Bio Path Holdings Inc |
Terapia de combinacion con oligonucleotidos antisentido liposomales.
|
EP3522933B1
(de)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Verfahren zur herstellung von antikörperarzneimittelkonjugaten
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
US11883430B2
(en)
|
2016-11-09 |
2024-01-30 |
Musc Foundation For Research Development |
CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
|
CN110381997A
(zh)
|
2016-12-12 |
2019-10-25 |
茂体外尔公司 |
用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
|
RS61795B1
(sr)
|
2017-02-08 |
2021-06-30 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin antitela
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
EP3586136B1
(de)
|
2017-02-24 |
2023-11-08 |
Board Of Regents, The University Of Texas System |
Test zum nachweis von pankreaskarzinom im frühstadium
|
WO2018192944A1
(en)
|
2017-04-18 |
2018-10-25 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
EP3612234B1
(de)
|
2017-04-20 |
2024-03-13 |
ADC Therapeutics SA |
Kombinationstherapie mit anti-axl-antikörper-arzneimittel-konjugat
|
CA3060988A1
(en)
|
2017-05-12 |
2018-11-15 |
Board Of Regents, The University Of Texas System |
Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
|
US10865403B2
(en)
|
2017-05-12 |
2020-12-15 |
Board Of Regents, The University Of Texas System |
Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
|
AU2018277545A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
CA3065301A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
CN110997724A
(zh)
|
2017-06-06 |
2020-04-10 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
MX2019015042A
(es)
|
2017-06-14 |
2020-08-06 |
Adc Therapeutics Sa |
Regimen de dosificacion.
|
AU2018316532B2
(en)
|
2017-08-18 |
2022-11-24 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
IL273387B2
(en)
|
2017-09-20 |
2023-10-01 |
Ph Pharma Co Ltd |
Thylanstatin analogs
|
EP4116327A1
(de)
|
2017-10-11 |
2023-01-11 |
Board Of Regents, The University Of Texas System |
Menschliche pd-l1-antikörper und verfahren zu ihrer verwendung
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
KR20200135986A
(ko)
|
2018-03-19 |
2020-12-04 |
멀티비르 인코포레이티드 |
종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
|
WO2019182896A1
(en)
|
2018-03-23 |
2019-09-26 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
US20210361655A1
(en)
|
2018-03-27 |
2021-11-25 |
Board Of Regents, The University Of Texas System |
Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
CN108624589B
(zh)
*
|
2018-04-17 |
2021-12-17 |
广州永诺生物科技有限公司 |
环状RNA circ-ERBB2及其检测试剂与应用
|
CN108715603A
(zh)
*
|
2018-06-08 |
2018-10-30 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
CN108484732A
(zh)
*
|
2018-06-08 |
2018-09-04 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
JP2022505450A
(ja)
|
2018-10-24 |
2022-01-14 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
コンジュゲート化された化学的分解誘導物質および使用方法
|
EP3883955A1
(de)
|
2018-11-19 |
2021-09-29 |
Board of Regents, The University of Texas System |
Modularer, polycistronischer vektor für car- und tcr-transduktion
|
CA3121027A1
(en)
|
2018-11-28 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
US20220033778A1
(en)
|
2018-11-29 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
EP3920889A4
(de)
|
2019-02-08 |
2022-12-07 |
Board of Regents, The University of Texas System |
Telomerasehaltige exosomen zur behandlung von krankheiten im zusammenhang mit altersbedingter organdysfunktion
|
US20220220440A1
(en)
|
2019-05-09 |
2022-07-14 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
EP3968971A1
(de)
|
2019-05-17 |
2022-03-23 |
Cancer Prevention Pharmaceuticals, Inc. |
Verfahren zur behandlung familiärer adenomatöser polyposis
|
WO2021016062A1
(en)
|
2019-07-19 |
2021-01-28 |
The Children's Hospital Of Philadelphia |
Chimeric antigen receptors containing glypican 2 binding domains
|
EP4027978A1
(de)
|
2019-09-13 |
2022-07-20 |
Elektrofi, Inc. |
Zusammensetzungen und verfahren zur abgabe von therapeutischen biologika zur behandlung von krankheiten
|
CN114729045A
(zh)
|
2019-09-26 |
2022-07-08 |
斯特库比公司 |
对糖基化的ctla-4特异性的抗体及其使用方法
|
JP2022552282A
(ja)
|
2019-10-09 |
2022-12-15 |
エスティーキューブ アンド カンパニー |
グリコシル化lag3に対して特異的な抗体およびその使用方法
|
US20220380765A1
(en)
|
2019-11-02 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
MX2022008412A
(es)
|
2020-01-07 |
2022-08-08 |
Univ Texas |
Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer.
|
CA3168337A1
(en)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
US20230212256A1
(en)
|
2020-05-21 |
2023-07-06 |
Board Of Regents, The University Of Texas System |
T cell receptors with vgll1 specificity and uses thereof
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
US20230266325A1
(en)
|
2020-06-30 |
2023-08-24 |
Lunglife Ai, Inc. |
Methods for detecting lung cancer
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
US20230051406A1
(en)
|
2020-11-13 |
2023-02-16 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
US20220162288A1
(en)
|
2020-11-25 |
2022-05-26 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
CA3205538A1
(en)
|
2021-01-19 |
2022-07-28 |
Han XIAO |
Bone-specific delivery of polypeptides
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
WO2023014922A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
WO2023020612A1
(en)
*
|
2021-08-20 |
2023-02-23 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Genetically modified non-human animal with human or chimeric her2
|
IL311790A
(en)
|
2021-10-05 |
2024-05-01 |
Chang Hao Ming |
Natural killer cells and methods of their use
|
CN113699221B
(zh)
*
|
2021-10-19 |
2023-10-10 |
广州吉赛医疗科技有限公司 |
HER2 mRNA及环状RNA多重荧光定量PCR检测引物探针及其应用
|
AU2022372894A1
(en)
|
2021-10-20 |
2024-04-18 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
CN114262689A
(zh)
*
|
2021-12-17 |
2022-04-01 |
上海纳米技术及应用国家工程研究中心有限公司 |
一种快速检测cd19/cd20-car-t细胞活性的方法
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
WO2023172514A1
(en)
|
2022-03-07 |
2023-09-14 |
Catamaran Bio, Inc. |
Engineered immune cell therapeutics targeted to her2 and methods of use thereof
|
US20230365708A1
(en)
|
2022-04-01 |
2023-11-16 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
WO2023230531A1
(en)
|
2022-05-24 |
2023-11-30 |
Lunglife Ai, Inc. |
Methods for detecting circulating genetically abnormal cells
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|